SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lazzarini L, Lalla F, de, Mader JT. Long bone osteomyelitis. Curr Infect Dis Rep 2002; 4: 43945.
  • 2
    Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9: 12738.
  • 3
    Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, 5th edn. on CD-ROM. 5th éd. Philadelphia, PA: Churchill Livingstone, 2000.
  • 4
    Dornbusch K, Carlström A, Hugo H, Lidströlm A. Antibacterial activity of clindamycin and lincomycin in human bone. J Antimicrob Chemother 1977; 3: 15360.
  • 5
    Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol 1972; 12: 25962.
  • 6
    Plott MA, Roth H. Penetration of clindamycin into synovial fluid. Clin Pharmacol Ther 1970; 11: 57780.
  • 7
    Mayberry-Carson KJ, Mayberry WR, Tober-Meyer BK, Costerton JW, Lambe DW Jr. An electron microscopic study of the effect of clindamycin on adherence of Staphylococcus aureus to bone surfaces. Microbios 1986; 45: 2132.
  • 8
    Mayberry-Carson KJ, Tober-Meyer B, Lambe DW Jr, Costerton JW. An electron microscopic study of the effect of clindamycin therapy on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios 1986; 48: 189206.
  • 9
    Gisby J, Beale AS, Bryant JE, Toseland CDN. Staphylococcal osteomyelitis – a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J Antimicrob Chemother 1994; 34: 75564.
  • 10
    Mader JT, Adams K, Morrison L. Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33: 17604.
  • 11
    El Samad Y, Havet E, Bentayeb H, Olory B, Canarelli B, Lardanchet J-F, Douadi Y, Rousseau F, Lescure FX, Mertl P, Eb F, Schmit JL. Treatment of osteoarticular infections with clindamycin in adults. Med Mal Infect 2008; 38: 46570.
  • 12
    Geddes AM, Dwyer NSJ, Ball AP, Amos RS. Clindamycin in bone and joint infections. J Antimicrob Chemother 1977; 3: 5017.
  • 13
    Zeller V, Dzeing-Ella A, Kitzis M-D, Ziza J-M, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010; 54: 8892.
  • 14
    Pharmacia Limited. Dalacin, Summary of Product Characteristics. Sandwich: Pharmacia Limited, 2010 25 May Posting Date.
  • 15
    Lavielle M, Mentré F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 2007; 34: 22949.
  • 16
    Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 55869.
  • 17
    Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299314.
  • 18
    Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 14351.
  • 19
    Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 15466.
  • 20
    Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Int J Antimicrob Agents 2011; 38: 3016.
  • 21
    Zeller V, Desplaces N. Antibiothérapie des infections ostéoarticulaires à pyogènes chez l'adulte?: principes et modalités. Rev Rhum 2006; 73: 18390.
  • 22
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 110. quiz 11–12.